FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * LeCointe-Cephas Lisa 2. Issuer Name and Ticker or Trading Symbol Merck & Co., Inc. [ MRK ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP Chief Ethics & Com Officer
(Last)          (First)          (Middle)
MERCK & CO., INC., 2000 GALLOPING HILL ROAD		 3. Date of Earliest Transaction (MM/DD/YYYY)
5/3/2022
(Street)
KENILWORTH, NJ 07033
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  5/4/2022    M    813  A $87.10  3942.781  D   
Common Stock  5/4/2022    F    279  D $87.10  3663.781 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $87.10  5/3/2022    A     11650      5/3/2023 (2) 5/2/2032  Common Stock  11650  $0  11650  D   
Restricted Stock Unit   (3) 5/3/2022    A     2067      5/3/2023 (4) 5/3/2025  Common Stock  2067  $0  2067  D   
Restricted Stock Unit   (3) 5/4/2022    M        813 (5)  5/4/2022 (6) 5/4/2024  Common Stock  813  $0  1629 (5) D   

Explanation of Responses:
(1)  Holdings include shares acquired in dividend reinvestment transactions.
(2)  The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025.
(3)  Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
(4)  These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025.
(5)  Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
(6)  These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
LeCointe-Cephas Lisa
MERCK & CO., INC.
2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033

SVP Chief Ethics & Com Officer

Signatures
/s/ Kelly E. W. Grez as attorney-in-fact for Lisa LeCointe-Cephas 5/5/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Merck (NYSE:MRK)
Historical Stock Chart
Von Jul 2022 bis Aug 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Aug 2021 bis Aug 2022 Click Here for more Merck Charts.